A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients with Schizophrenia in General Psychiatric Practices

Mise à jour : Il y a 5 ans
Référence : EUCTR2004-001181-41

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the effectiveness of eight weeks of treatment with aripiprazole in patients diagnosed with schizophrenia or schizoaffective disorder who are treated in an outpatient psychiatric setting. The overall effectiveness of aripiprazole will be evaluated by use of the CGI-I scale. The evaluation of effectiveness will encompass the patients’ psychopathology, including efficacy, safety and tolerability.


Critère d'inclusion

  • Schizophrenia or schizoaffective disorder